Alzheimer's disease (AD) causes a severe depletion of cholinergic innervation in the cerebral cortex and hippocampal formation (Geula & Mesulam, 1999; Beach et al., 2000) . The cholinergic projections that degenerate in AD arise from the basal forebrain and influence all aspects of neural activity, especially those related to memory and attention (Mesulam, 1996) . Normal cholinergic function depends on the rapid hydrolytic inactivation of acetylcholine (ACh) by cholinesterases. Partial inhibition of cholinesterases can prolong the effect of ACh and is the principal mode of action for all four drugs currently approved for the treatment of AD, tacrine (Cognex), donepezil (Aricept), rivastigmine (Exelon), and galantamine (Reminyl).
The human brain contains two cholinesterases: acetylcholinesterase (AChE) encoded by a gene on chromosome 7, and butyrylcholinesterase (BChE) encoded by a gene on chromosome 3. Acetylcholinesterase (EC 3.1.1.7) is by far the more prominent of the two, and the only one consistently associated with cholinergic and cholinoceptive neurons. Butyrylcholinesterase (EC 3.1.1.8) is found in much lower concentrations, is traditionally known as the "pseudo" cholinesterase and is thought to have a much more restricted distribution in the brain (Mesulam, 2000) . Although there is no convincing evidence that BChE plays a useful role in central cholinergic transmission, there is evidence that it modulates cholinergic transmission in smooth muscle (Norel et al., 1993) . These considerations have led to the belief that the selective inhibition of AChE but not of BChE should be pursued in the treatment of AD since this is likely to offer the desirable CNS effects without triggering autonomic complications.
This traditional view of BChE has recently been challenged by evidence gathered in AChE knockout mice (Xie et al., 2000) . Histochemical experiments in 
